Dr. Stuart C. Gordon, M.D.
Gastroenterology (Gastroenterology Physician)
- Medicare participating
At a glance
- Medical school
- Wayne State University School of Medicine (1979)
- Years since graduation
- 47
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 229
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1979Medical school: Wayne State University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Gastroenterology Physician primary
MI license 4301043059
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Henry Ford Health Hospital Detroit, MI
- Henry Ford Macomb Hospital Clinton Township, MI
- Henry Ford Health West Bloomfield Hospital W Bloomfield, MI
- Henry Ford Allegiance Health Jackson, MI
- Wyandotte Hospital and Medical Center Wyandotte, MI
Medical groups
- Henry Ford Health System (2,570 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 229
- Services billed
- 288
- Patients’ average age
- 71
| Service | Times | Patients |
|---|---|---|
| Measurement of liver stiffness | 115 | 114 |
| Established patient office or other outpatient visit, 30-39 minutes | 102 | 82 |
| New patient office or other outpatient visit, 45-59 minutes | 22 | 22 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Ursodiol Other prescribers in Detroit, MI | 250 |
| Vemlidy (tenofovir alafenamide) | 163 |
| Xifaxan (rifaximin) Other prescribers in Detroit, MI | 140 |
| Prednisone Other prescribers in Detroit, MI | 89 |
| Entecavir | 81 |
| Azathioprine Other prescribers in Detroit, MI | 52 |
| Spironolactone Other prescribers in Detroit, MI | 35 |
| Furosemide Other prescribers in Detroit, MI | 34 |
| Ocaliva (obeticholic acid) | 30 |
| Lactulose Other prescribers in Detroit, MI | 28 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 3 companies reported 49 payments worth $69,146 in total to this clinician.
| Gilead Sciences, Inc. | $52,075 |
|---|---|
| GlaxoSmithKline, LLC. | $15,394 |
| Ipsen Biopharmaceuticals, Inc | $1,677 |
| Compensation for services other than consulting (speaking, faculty) | $33,740 |
|---|---|
| Consulting Fee | $23,430 |
| Travel and Lodging | $10,380 |
| Food and Beverage | $1,596 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. May 19, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4127767;AHM;10004721 | $6,440 |
| Gilead Sciences, Inc. Jun 27, 2025 | Consulting Fee Livdelzi · INFLAM Company’s description;4147233;VEM US;10004721 | $6,190 |
| Gilead Sciences, Inc. Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4119324;AHM;10004721 | $4,930 |
| Gilead Sciences, Inc. Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4112502;AHM;10004721 | $4,930 |
| Gilead Sciences, Inc. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4121523;AHM;10004721 | $4,930 |
| Gilead Sciences, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4128161;AHM;10004721 | $4,930 |
| GlaxoSmithKline, LLC. Mar 18, 2025 | Consulting Fee | $4,400 |
| GlaxoSmithKline, LLC. Jul 29, 2025 | Consulting Fee | $4,400 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Consulting Fee | $4,000 |
| Gilead Sciences, Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4119634;AHM;10004721 | $3,790 |
All 29 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| Gilead Sciences, Inc. Nov 24, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4264866;AHM;10004721 | $3,790 |
| GlaxoSmithKline, LLC. Jul 29, 2025 | Consulting Fee | $4,400 |
| Gilead Sciences, Inc. Jul 24, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4128161;AHM;10004721 | $4,930 |
| Gilead Sciences, Inc. Jul 17, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to South San Francisco, CA Company’s description;4146700;VEM US;10004721 | $120 |
| Gilead Sciences, Inc. Jul 17, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to South San Francisco, CA Company’s description;4149220;VEM US;10004721 | $120 |
| Gilead Sciences, Inc. Jul 16, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Grand Rapids, MI · in-kind Company’s description;4327813;AHM;10004721 | $845 |
| Gilead Sciences, Inc. Jun 27, 2025 | Consulting Fee Livdelzi · INFLAM Company’s description;4147233;VEM US;10004721 | $6,190 |
| Gilead Sciences, Inc. Jun 18, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4119634;AHM;10004721 | $3,790 |
| Gilead Sciences, Inc. Jun 16, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Fenton, MI · in-kind Company’s description;4327748;AHM;10004721 | $494 |
| Gilead Sciences, Inc. Jun 12, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to South San Francisco, CA · in-kind Company’s description;4147078;VEM US;10004721 | $735 |
| Gilead Sciences, Inc. Jun 12, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to South San Francisco, CA · in-kind Company’s description;4147109;VEM US;10004721 | $488 |
| Gilead Sciences, Inc. Jun 12, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to South San Francisco, CA · in-kind Company’s description;4147107;VEM US;10004721 | $53.21 |
| Gilead Sciences, Inc. Jun 6, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4121523;AHM;10004721 | $4,930 |
| Gilead Sciences, Inc. Jun 2, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Saginaw, MI · in-kind Company’s description;4328196;AHM;10004721 | $845 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $1,237 |
| Ipsen Biopharmaceuticals, Inc May 31, 2025 | Travel and Lodging IQIRVO · Rare Disease · travel to Dallas, TX · in-kind | $203 |
| Gilead Sciences, Inc. May 21, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Walloon Lake, MI · in-kind Company’s description;4327942;AHM;10004721 | $2,383 |
| Gilead Sciences, Inc. May 19, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4127767;AHM;10004721 | $6,440 |
| Gilead Sciences, Inc. May 14, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Walloon Lake, MI · in-kind Company’s description;4116750;AHM;10004721 | $278 |
| Gilead Sciences, Inc. Apr 15, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4112502;AHM;10004721 | $4,930 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Consulting Fee | $4,000 |
| GlaxoSmithKline, LLC. Apr 3, 2025 | Travel and Lodging travel to Durham, NC | $22.68 |
| Gilead Sciences, Inc. Mar 27, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Cleveland, OH · in-kind Company’s description;4328083;AHM;10004721 | $1,250 |
| Gilead Sciences, Inc. Mar 24, 2025 | Compensation for services other than consulting (speaking, faculty) Livdelzi · INFLAM Company’s description;4119324;AHM;10004721 | $4,930 |
| Gilead Sciences, Inc. Mar 19, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Lansing, MI · in-kind Company’s description;4098539;AHM;10004721 | $780 |
| GlaxoSmithKline, LLC. Mar 18, 2025 | Consulting Fee | $4,400 |
| Gilead Sciences, Inc. Feb 18, 2025 | Travel and Lodging Livdelzi · INFLAM · travel to Jamestown, NY · in-kind Company’s description;4327882;AHM;10004721 | $527 |
| Gilead Sciences, Inc. Feb 5, 2025 | Consulting Fee Livdelzi · INFLAM Company’s description;4218362;VEM US;10004721 | $2,040 |
| GlaxoSmithKline, LLC. Jan 28, 2025 | Consulting Fee | $2,400 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 4 companies. The companies reported $337,907 in research payments for these studies, mostly to the institutions running them.
- Implementing pruritus assessment into the routine clinical care of pat
GlaxoSmithKline, LLC. - Study name not reported
GlaxoSmithKline, LLC. - An Open Label Long-Term Study to Evaluate the Safety and Tolerability of Seladelpar in Subjects With Primary Biliary Cholangitis (PBC)
Gilead Sciences, Inc. - A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)…
Gilead Sciences, Inc. - A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Seladelpar on Clinical Outcomes in Patients With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
Gilead Sciences, Inc. - TAK-999-3002 A Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Fazirsiran in the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease With METAVIR Sta…
Takeda Pharmaceuticals U.S.A., Inc. - A prospective, multi centre study (b-sure) to evaluate long term durab
GlaxoSmithKline, LLC. - Study to check the safety of fazirsiran and learn if fazirsiran can help people with liver disease and scarring (fibrosis) due to an abnormal version of ALPHA-1 antitrypsin protein
Takeda Pharmaceuticals U.S.A., Inc. - Phase 3 multicenter, randomized, double-blind, study to assess the eff
GlaxoSmithKline, LLC. - Linerixibat (GSK2330672) ileal bile acid transport (ibat) inhibitor (o
GlaxoSmithKline, LLC.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.